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THE VIRTUAL EXPLOSION of new scientific information brought about by the AIDS epidemic has made it difficult for pharmacists and other healthcare professionals to remain abreast of the latest information in this area. Therefore, it was considered important to establish a specialty column for topics concerning "HIV and AIDS." The goal of this column is to capture new information and present it in a timely manner to healthcare providers serving HIV-infected children and adults.
The tenth anniversary of the AIDS epidemic was marked last June with both sadness and hope. During these first ten years, approximately 180000 cases of AIDS and over 100 000 AIDS-related deaths were reported to the Centers for Disease Control (CDC)} By the year 2000, the World Health Organization projects that 40 million people worldwide will be infected with mV. 2 As the second decade of the epidemic begins, we see that the epidemiology of HIV infection is changing, shifting from a population of primarily white homosexual/bisexual men to one of heterosexual men, women, and children. Moreover, the spectrum of clinical conditions associated with mv infection is ever widening, resulting in revision of the CDC defmition of AIDS.
Although mv infection and AIDS are often felt to be synonymous with suffering and death, there is reason to believe that the medical progress made during the first decade of the epidemic will continue into the next. Although some might argue differently, noteworthy progress in the fight against AIDS has been made in the past few years. Since 1986, no fewer than eight new drugs have been approved by the Food and Drug Administration (FDA) for the treat- therapy, such as bone marrow suppression and the development of in vitro viral resistance, have prompted the development of other antiretrovirals such as didanosine and dideoxycytidine. During the next ten years, use of combination antiretroviral therapy will progressively become more common. The second decade of mv infection will also herald the development of numerous other new agents such as non-nucleoside reverse transcriptase inhibitors, HIV protease inhibitors, biologic response modifiers, and inhibitors of regulatory proteins.
Research efforts against HfV infection in this country have intensified and become more organized. Working together, representatives from pharmaceutical companies, the federal government (National Institutes of Health [NIH] and the FDA), and the medical and lay communities have made major contributions in the fight against AIDS. Such a joint effort is exemplified by the NIH-sponsored AIDS Clinical Trials Group (ACTG), which has completed or has in progress over 150 clinical studies since its organization in 1987. The membership of every ACTG core committee includes a representative from each constituency group listed above, as well as members from activist groups such as AIDS Coalition to Unleash Power (ACT-UP) and the Gay Men's Health Crisis. Changes in the drug development process brought about by the HIV epidemic should facilitate clinical research in other scientific and therapeutic areas. The FDA has assumed the role of a drug development advocate, offering greater assistance early in the drug development and review processes in order to speed the delivery of new drug entities to the very ill patients who so badly need them.
In the future, pharmacists and other healthcare professionals will have ever-expanding roles in the care of patients with HIV infection. The number of infected people will continue to rise, and these individuals will be taking more medications than before. Unique opportunities and important contributions await those pharmacists who can provide high-quality pharmaceutical care to patients at all stages of HIV infection. It is our hope that the information in this column will be a useful resource for those pharmacists "on the lines" caring for patients with HIV infection.
